[Edaily Reporter Park Jeong-soo] #Samchundang Pharmaceutical concluded its overseas investor roadshow (NDR) in Hong Kong and Singapore and shared its business strategy with global investors.
According to Samchundang Pharmaceutical on the 11th, the company held a CEO Non-Deal Roadshow (NDR) for overseas institutional investors in Hong Kong and Singapore on the 8th and 9th. The event was organized by Korea Investment & Securities. In particular, Samchundang Pharmaceutical plans to use this NDR to accelerate not only overseas investment attraction but also its entry into global markets.
During the event, Samchundang Pharmaceutical presented the current status of its Eylea biosimilar business and its pipeline development strategy based on S-PASS, its proprietary oral drug delivery platform.
As one of the companies that has commercialized the Eylea biosimilar, Samchundang Pharmaceutical is leveraging its commercialization experience to expand sales in key markets such as Canada and strengthen global partnerships.
The company also introduced the S-PASS platform, which it is cultivating as a core growth engine, to investors. S-PASS is a drug delivery platform for the development of oral peptide and protein therapeutics, and is being utilized in the development of oral semaglutide, tirzepatide, and insulin.
In particular, the company’s recent approval from the European Medicines Agency (EMA) for a Phase 1 clinical trial of an oral insulin was highlighted as a key point of interest. The company aims to secure key clinical results within this year.
A Samchundang Pharmaceutical official stated, “Through this NDR, we were able to directly introduce our commercialization capabilities and the competitiveness of our platform technology to global investors,” adding, “Based on our experience with the Eylea biosimilar business, we will continue to demonstrate the value of the S-PASS platform in the global market.”
The spokesperson continued, “Key milestones scheduled for the second half of the year include an official response from the U.S. Food and Drug Administration (FDA) regarding the approval of our oral semaglutide generic, as well as the oral insulin clinical trial and the development of oral tirzepatide,” adding, “We plan to proceed with these initiatives without delay to expand our presence in the global market.”